PT-141 is a peptide that works through the brain’s melanocortin signaling system, targeting pathways involved in sexual desire and arousal. Unlike medications such as Viagra that primarily affect blood flow, PT-141 acts centrally on the pathways involved in wanting, desire, and sexual response.

Potential benefits: increased sexual desire, improved arousal and responsiveness, and support for women experiencing distressing low libido. Bremelanotide is FDA-approved as Vyleesi for acquired, generalized HSDD in certain premenopausal women; other uses of PT-141 fall outside that FDA-approved indication.

Short product-card version:

PT-141 | Libido + Arousal

Supports sexual desire, arousal & responsiveness by targeting the brain pathways involved in sexual motivation.